Public Employees Retirement System of Ohio Invests $14.77 Million in IDEXX Laboratories, Inc. $IDXX

Public Employees Retirement System of Ohio acquired a new stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm acquired 28,050 shares of the company’s stock, valued at approximately $14,767,000.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. J.Safra Asset Management Corp acquired a new stake in shares of IDEXX Laboratories in the second quarter valued at approximately $25,000. SHP Wealth Management acquired a new position in shares of IDEXX Laboratories during the fourth quarter worth approximately $26,000. Elevation Wealth Partners LLC grew its holdings in IDEXX Laboratories by 188.2% in the 2nd quarter. Elevation Wealth Partners LLC now owns 49 shares of the company’s stock worth $26,000 after buying an additional 32 shares in the last quarter. Virtus Advisers LLC bought a new position in IDEXX Laboratories in the 3rd quarter worth approximately $26,000. Finally, WealthCollab LLC acquired a new stake in IDEXX Laboratories in the 2nd quarter valued at approximately $30,000. 87.84% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on IDXX. Citigroup lifted their target price on IDEXX Laboratories from $650.00 to $670.00 and gave the company a “neutral” rating in a research note on Wednesday, August 5th. UBS Group raised their price target on IDEXX Laboratories from $620.00 to $670.00 and gave the company a “neutral” rating in a report on Wednesday, August 5th. Barclays cut their price objective on shares of IDEXX Laboratories from $800.00 to $710.00 and set an “overweight” rating on the stock in a research note on Tuesday, August 11th. Weiss Ratings lowered shares of IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a research report on Thursday. Finally, Wall Street Zen cut shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Sunday, July 12th. Six investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat.com, IDEXX Laboratories presently has an average rating of “Moderate Buy” and a consensus price target of $747.00.

IDEXX Laboratories Price Performance

NASDAQ:IDXX opened at $554.99 on Monday. The company has a quick ratio of 0.87, a current ratio of 1.17 and a debt-to-equity ratio of 0.19. The business’s 50-day moving average price is $559.01 and its 200 day moving average price is $573.33. IDEXX Laboratories, Inc. has a 52-week low of $518.55 and a 52-week high of $769.98. The firm has a market cap of $43.72 billion, a P/E ratio of 39.03, a PEG ratio of 2.96 and a beta of 1.54.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings results on Tuesday, August 4th. The company reported $4.27 earnings per share for the quarter, beating analysts’ consensus estimates of $3.94 by $0.33. IDEXX Laboratories had a net margin of 25.03% and a return on equity of 71.96%. The company had revenue of $1.22 billion during the quarter, compared to the consensus estimate of $1.20 billion. During the same period in the prior year, the company earned $3.50 EPS. IDEXX Laboratories’s revenue was up 9.7% on a year-over-year basis. IDEXX Laboratories has set its FY 2026 guidance at 14.690-14.940 EPS. As a group, sell-side analysts predict that IDEXX Laboratories, Inc. will post 14.81 earnings per share for the current fiscal year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.